2024
Predicting clinical outcomes of SARS-CoV-2 infection during the Omicron wave using machine learning
Cogill S, Nallamshetty S, Fullenkamp N, Heberer K, Lynch J, Lee K, Aslan M, Shih M, Lee J. Predicting clinical outcomes of SARS-CoV-2 infection during the Omicron wave using machine learning. PLOS ONE 2024, 19: e0290221. PMID: 38662748, PMCID: PMC11045098, DOI: 10.1371/journal.pone.0290221.Peer-Reviewed Original ResearchConceptsHigh-risk groupSARS-CoV-2 infectionAnticoagulant useAdverse outcomesPredictor of adverse outcomesHigher risk of adverse outcomesLower body mass indexRisk of adverse outcomesVaccination of high-risk groupsOral anticoagulant useOutcome of SARS-CoV-2 infectionRetrospective longitudinal observational studySARS-CoV-2U.S. Veterans Health AdministrationClinical outcomes of SARS-CoV-2 infectionIdentification of patientsBody mass indexVeterans Health AdministrationPredictors of hospitalizationEscalation of careLongitudinal observational studyClinical outcomesOmicron SARS-CoV-2 variantSARS-CoV-2 variantsUnvaccinated patients
2023
Metformin prescription for U.S. veterans with prediabetes, 2010–2019
Gulanski B, Goulet J, Radhakrishnan K, Ko J, Li Y, Rajeevan N, Lee K, Heberer K, Lynch J, Streja E, Mutalik P, Cheung K, Concato J, Shih M, Lee J, Aslan M. Metformin prescription for U.S. veterans with prediabetes, 2010–2019. Journal Of Investigative Medicine 2023, 72: 139-150. PMID: 37668313, DOI: 10.1177/10815589231201141.Peer-Reviewed Original ResearchConceptsBody mass indexVeterans Health AdministrationIncident prediabetesHigh riskHealth AdministrationRetrospective observational cohort studyType 2 diabetes mellitusUse of metforminObservational cohort studyProportion of veteransMetformin prescribingGestational diabetesCohort studyMetformin prescriptionDiabetes mellitusDiabetes preventionMass indexCardiovascular diseaseMultivariable modelPrediabetesSubset of individualsMetforminU.S. veteransHealthcare systemVeteransEffectiveness of Nirmatrelvir-Ritonavir Against the Development of Post-COVID-19 Conditions Among U.S. Veterans : A Target Trial Emulation.
Ioannou G, Berry K, Rajeevan N, Li Y, Mutalik P, Yan L, Bui D, Cunningham F, Hynes D, Rowneki M, Bohnert A, Boyko E, Iwashyna T, Maciejewski M, Osborne T, Viglianti E, Aslan M, Huang G, Bajema K. Effectiveness of Nirmatrelvir-Ritonavir Against the Development of Post-COVID-19 Conditions Among U.S. Veterans : A Target Trial Emulation. Annals Of Internal Medicine 2023, 176: 1486-1497. PMID: 37903369, PMCID: PMC10620954, DOI: 10.7326/m23-1394.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntiviral AgentsCOVID-19COVID-19 Drug TreatmentFemaleHumansMaleRetrospective StudiesRitonavirSARS-CoV-2ThromboembolismUnited StatesVeteransConceptsAcute COVID-19Veterans Health AdministrationUntreated comparatorsThromboembolic eventsCOVID-19Severe COVID-19Target trial emulationSARS-CoV-2Post COVID-19 conditionIndex dateVenous thromboembolismBaseline characteristicsCumulative incidencePulmonary embolismAcute infectionMedian ageOral antiviralsTrial emulationVHA careOutpatient treatmentInternational ClassificationHealth AdministrationU.S. veteransVeterans AffairsOrgan systemsEffectiveness of COVID-19 Treatment With Nirmatrelvir–Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes
Bajema K, Berry K, Streja E, Rajeevan N, Li Y, Mutalik P, Yan L, Cunningham F, Hynes D, Rowneki M, Bohnert A, Boyko E, Iwashyna T, Maciejewski M, Osborne T, Viglianti E, Aslan M, Huang G, Ioannou G. Effectiveness of COVID-19 Treatment With Nirmatrelvir–Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes. Annals Of Internal Medicine 2023, 176: m22-3565. PMID: 37276589, PMCID: PMC10243488, DOI: 10.7326/m22-3565.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntiviral AgentsCOVID-19COVID-19 Drug TreatmentCOVID-19 VaccinesFemaleHumansMaleRetrospective StudiesRitonavirSARS-CoV-2VeteransConceptsVeterans Health AdministrationCOVID-19 symptom onsetCOVID-19-related outcomesSevere COVID-19Six-month outcomesCOVID-19 vaccinationCOVID-19 treatmentCOVID-19SARS-CoV-2Percent of participantsUntreated control participantsCause mortalitySymptom onsetMedian ageOral antiviralsVHA careOutpatient treatmentHospitalizationHealth AdministrationDay 31U.S. veteransVariant transmissionMost veteransVeterans AffairsOne month